ArticleHepatology (Baltimore, Md.)2007
Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis.
Article in Hepatology (Baltimore, Md.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00518440 (A Multi-Center Trial to Study Acute Liver Failure in Adults), which is not on this map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center Trial to Study Acute Liver Failure in Adults
Who cites it
59 citing papers in PubMed, 121 citations in OpenAlex.
- Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2015Trial
- Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis.Journal of translational autoimmunity · 2026Review
- Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis.Journal of clinical and translational hepatology · 2025Article
- A Case of Evolving Hepatotoxicity Following Systemic Drug Reaction to Isoniazid-Rifapentine (3HP).Case reports in hepatology · 2025Article
- Evolutionary relationship between antimitochondrial antibody positivity and primary biliary cholangitis in Taiwan: a 16-year hospital cohort study.Therapeutic advances in gastroenterology · 2024Article
- Exosomal Long Noncoding RNAs Serve as Biomarkers for Liver Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Review
- Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021).Journal of clinical and translational hepatology · 2023Article
- Management of Acute Liver Failure: Update 2022.Seminars in liver disease · 2022Article
- Challenges and Future of Drug-Induced Liver Injury Research-Laboratory Tests.International journal of molecular sciences · 2022Review
- Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry.The American journal of gastroenterology · 2022Article
- APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.Hepatology international · 2022Article
- [Guidelines on the diagnosis and management of primary biliary cholangitis (2021)].Zhonghua nei ke za zhi · 2021Article
- Autoimmune liver disease-associated serologic profiling in Chinese patients with acute hepatitis E virus infection.Immunologic research · 2021Article
- Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury.British journal of clinical pharmacology · 2020Article
- Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody-positive subjects over six years of follow-up.Journal of internal medicine · 2020Article
- Detection of Anti-mitochondrial Antibodies Accompanied by Drug-induced Hepatic Injury due to Atorvastatin.Internal medicine (Tokyo, Japan) · 2019Article
- [Immune-mediated cholangiopathies : Diagnostic and therapeutic challenges].Der Radiologe · 2019Review
- A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity.Internal medicine (Tokyo, Japan) · 2018Article
- Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance.Frontiers in immunology · 2018Review
- Clinical and Pathological Characteristics of Autoimmune Hepatitis with Acute Presentation.Canadian journal of gastroenterology & hepatology · 2018Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
unlabelledIn our previous work, including analysis of more than 10,000 sera from control patients and patients with a variety of liver diseases, we have demonstrated that with the use of recombinant autoantigens, antimitochondrial autoantibodies (AMAs) are only found in primary biliary cirrhosis (PBC) and that a positive AMA is virtually pathognomonic of either PBC or future development of PBC. Although the mechanisms leading to the generation of AMA are enigmatic, we have postulated that xenobiotic-induced and/or oxidative modification of mitochondrial autoantigens is a critical step leading to loss of tolerance. This thesis suggests that a severe liver oxidant injury would lead to AMA production. We analyzed 217 serum samples from 69 patients with acute liver failure (ALF) collected up to 24 months post-ALF, compared with controls, for titer and reactivity with the E2 subunits of pyruvate dehydrogenase, branched chain 2-oxo-acid dehydrogenase, and 2-oxo-glutarate dehydrogenase. AMAs were detected in 28/69 (40.6%) ALF patients with reactivity found against all of the major mitochondrial autoantigens. In addition, and as further controls, sera were analyzed for autoantibodies to gp210, Sp100, centromere, chromatin, soluble liver antigen, tissue transglutaminase, and deaminated gliadin peptides; the most frequently detected nonmitochondrial autoantibody was against tissue transglutaminase (57.1% of ALF patients).
conclusionThe strikingly high frequency of AMAs in ALF supports the thesis that oxidative stress-induced liver damage may lead to AMA induction. The rapid disappearance of AMAs in these patients provides further support for the contention that PBC pathogenesis requires additional factors, including genetic susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.